Poor response rate to a continuous schedule of amifostine therapy for 'low/intermediate risk' myelodysplastic patients

British Journal of Haematology

Volumn 103, Issue 3, 1998, Pages 785-787

  Bowen, D T ^a,d   Denzlinger, C ^b   Brugger, W ^b   Culligan, D ^c   Gelly, K ^a   Adlakha, S ^a   Groves, M ^a   Hepburn, M ^e   Kanz, L ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NHS GRAMPIAN   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e NONE

Author keywords

'low risk'; Amifostine; Myelodysplasia; Response; Therapy

Indexed keywords

AMIFOSTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; PRURITUS;

AMIFOSTINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MYELODYSPLASTIC SYNDROMES; RADIATION-PROTECTIVE AGENTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031757027     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.01045.x     Document Type: Article

References (7)

1. Brasfield, F.M., Heaton, R., Glinsmann-Gibson, B., Obregon, Y., Talley, M., Taetle, R., Stogniew, M., Schein, P. & List, A.F. (1998) Phase I/II trial of subcutaneous Amifostine in patients with myelodysplastic syndrome (MDS). Proceedings ASCO, 17, 13.
2. Hellstrom Lindberg, E., Kanter Lewensohn, L. & Ost, A. (1997) Morphological changes and apoptosis in bone marrow from patients with myelodyplastic syndromes treated with granulocyte-CSF and erythropoietin. Leukemia Research, 21, 415-425.
3. Kempin, S., Sirott, M., Cecchi, G., Irwin, D., Gee, T., Stepan, D., Blum, R., Hamburg, S. & Wilson, E. (1998) Phase II study of Amifostine for the treatment of myelodysplastic syndrome (MDS). Proceedings ASCO, 17, 108.
4. List, A.F., Brasfield, F., Heaton, R., Glinsmann Gibson, B., Crook, L., Taetle, R. & Capizzi, R. (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood, 90, 3364-3369.
5. List, A.F., Heaton, R., Glinsmann Gibson, B. & Capizzi, R.L. (1996) Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Seminars in Oncologgy, 23, 58-63.
6. Mitchell, J.L., Judd, G.G., Diveley, R.R., Jr, Choe, C.Y. & Leyser, A. (1995) Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis, 16, 3063-3068.
7. + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. British Journal of Haematology, 99, 625-631.